| Margins | EBITDA before R&D margin at 24%; Net Profit Margin at 8%. |
|---|---|
| Order book | API segment bolstered by strong order book. |
| Demand visibility | Strong order book supporting 33% API growth. |
Growth
Revenue grew 26% to INR 21.50 Bn. EBITDA after R&D rose 21% YoY, while PAT grew 12% to INR 1.73 Bn.
Outlook
Pipeline includes 15+ US launches for FY27. Targets Water Neutrality and 50,000 trees by 2027; Net Zero by 2050.
Risks
Industry-wide interest rate and currency fluctuations; regulatory approvals; patent challenges; and manufacturing/marketing risks for approved products.
Investor Presentation filed with NSE, NSE: APLLTD. Summary written with AI assistance from the document.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹863.75
- Market cap
- ₹16,978 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 24.5×Sector 50.4×
- Promoter holding
- 69.87%+0.13% QoQ
- FII holding
- 4.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Debt & Borrowing: ₹100 Cr
Alembic Pharmaceuticals Limited has redeemed Commercial Papers (CP) worth Rs. 100 Crores. The redemption was completed on the maturity date of September 25, 2026.
- Value
- ₹100.0 Cr
Alembic Pharmaceuticals Debt & Borrowing: ₹150 Cr
Alembic Pharmaceuticals has redeemed Commercial Papers worth Rs. 150 Crore upon maturity on 23rd September 2026.
- Value
- ₹150.0 Cr
Alembic Pharmaceuticals Debt & Borrowing: ₹150 Cr
Alembic Pharmaceuticals has successfully redeemed Commercial Papers worth ₹150 Crore upon maturity. This confirms the repayment of the company's debt obligation.
- Value
- ₹150.0 Cr
Alembic Pharmaceuticals Business Update
Alembic Pharmaceuticals completed an unannounced USFDA onsite inspection at its Vadodara Bioequivalence Facility. The inspection concluded with zero Form 483 observations, a positive regulatory signal.
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.26 Cr
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in the UAE for Rs. 0.26 Crore to explore new business opportunities in pharmaceuticals.
- Value
- ₹0.26 Cr
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.25 Cr
Alembic Pharmaceuticals incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai to explore new business opportunities and distribution.
- Value
- ₹0.25 Cr